As of 2024-12-13, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -8.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 1,943.40 mil USD. TVTX's TTM EBITDA according to its financial statements is -240.10 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 18.0x | 15.4x |
| Forward P/E multiples | 14.4x - 29.8x | 22.4x |
| Fair Price | (44.61) - (54.41) | (56.93) |
| Upside | -338.8% - -391.3% | -404.8% |
| Date | EV/EBITDA |
| 2024-12-06 | -8.29 |
| 2024-12-05 | -8.35 |
| 2024-12-04 | -8.34 |
| 2024-12-03 | -8.34 |
| 2024-12-02 | -8.41 |
| 2024-11-29 | -8.14 |
| 2024-11-27 | -8.10 |
| 2024-11-26 | -8.23 |
| 2024-11-25 | -7.92 |
| 2024-11-22 | -7.94 |
| 2024-11-21 | -7.94 |
| 2024-11-20 | -7.80 |
| 2024-11-19 | -7.63 |
| 2024-11-18 | -7.63 |
| 2024-11-15 | -7.75 |
| 2024-11-14 | -8.02 |
| 2024-11-13 | -8.05 |
| 2024-11-12 | -8.12 |
| 2024-11-11 | -8.22 |
| 2024-11-08 | -8.51 |
| 2024-11-07 | -7.73 |
| 2024-11-06 | -7.60 |
| 2024-11-05 | -7.76 |
| 2024-11-04 | -7.89 |
| 2024-11-01 | -7.70 |
| 2024-10-31 | -7.67 |
| 2024-10-30 | -7.76 |
| 2024-10-29 | -7.98 |
| 2024-10-28 | -7.81 |
| 2024-10-25 | -7.68 |
| 2024-10-24 | -7.88 |
| 2024-10-23 | -7.84 |
| 2024-10-22 | -7.84 |
| 2024-10-21 | -7.89 |
| 2024-10-18 | -7.80 |
| 2024-10-17 | -7.94 |
| 2024-10-16 | -7.87 |
| 2024-10-15 | -7.74 |
| 2024-10-14 | -7.65 |
| 2024-10-11 | -7.28 |
| 2024-10-10 | -7.53 |
| 2024-10-09 | -7.71 |
| 2024-10-08 | -6.86 |
| 2024-10-07 | -6.87 |
| 2024-10-04 | -6.86 |
| 2024-10-03 | -6.30 |
| 2024-10-02 | -6.38 |
| 2024-10-01 | -6.42 |
| 2024-09-30 | -6.42 |
| 2024-09-27 | -6.43 |